Clinical Trial Update: Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients [Phase 1]

View source ↗

Summary

Phase 1 trial update on intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in patients with recurrent ovarian cancer, recurrent fallopian tube can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Allogeneic NK cell therapy (ex vivo-cultured allogeneic natural killer (NK) cells)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Recurrent Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma | Phase 1 | Status: COMPLETED